Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
PharmaCyte Biotech Inc, Medical Devices Deals, 2011 to YTD 2017 10
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Nuvilex Acquires Rights To Live-Cell Encapsulation Technology For Diabetes From SG Austria 12
Nuvilex Acquires Pancreatic Cancer Treatment Technology 13
Partnerships 14
PharmaCyte Biotech Partners with Translational Drug Development and Clinical Network Services 14
PharmaCyte Biotech Enters into Co-Development Agreement with University of Technology Sydney 15
Licensing Agreements 16
Nuvilex Enters into Licensing Agreement with University of Technology Sydney 16
Equity Offering 17
PharmaCyte Biotech Raises USD1 Million in Private Placement of shares 17
Nuvilex to Raise up to USD50 Million in Public Offering of Shares 18
Nuvilex Completes First Tranche Of Private Placement Of Shares For US$2 Million 19
Nuvilex Competes Private Placement Of Securities For US$1.5 Million 20
Acquisition 21
Nuvilex Acquires 14.5% Stake In SGAustria, Life Science Company 21
Nuvilex Acquires Bio Blue Bird For US$1.5 Million 22
PharmaCyte Biotech Inc – Key Competitors 23
PharmaCyte Biotech Inc – Key Employees 24
PharmaCyte Biotech Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Corporate Communications 26
Oct 10, 2017: PharmaCyte Biotech Appoints Dr. Raymond Tong to Board of Directors 26
Jul 26, 2017: PharmaCyte Biotech Appoints Dr. Linda S. Sher as Chief Medical Officer 27
Jul 10, 2017: PharmaCyte Biotech Appoints Dr. Michael M. Abecassis to Board of Directors 29
May 02, 2017: PharmaCyte Biotech Appoints Thomas Yuen to Board of Directors 30
Apr 03, 2017: PharmaCyte Biotech Appoints Dr. Mark Rabe Director of Cannabis Program Development 31
Legal and Regulatory 32
Nov 16, 2017: British Columbia Securities Commission Revokes Cease Trade Order on PharmaCyte Biotech Securities 32
Government and Public Interest 34
Feb 23, 2017: First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals 34
Product News 35
Dec 01, 2016: PharmaCyte Biotech Moves Closer to Enrolling Patients in Pancreatic Cancer Clinical Trial 35
Oct 17, 2017: PharmaCyte Biotech Research Identifies Enzyme Activity for Cannabinoid-Based Therapy to Fight Cancer 37
10/10/2016: PharmaCyte Biotech Cannabinoid Research Shows Promise for Success 38
07/07/2016: PharmaCyte Biotech Uses “Artificial Liver” to Treat Advanced Pancreatic Cancer 39
Jul 05, 2016: PharmaCyte’s Research on Medical Uses of Cannabinoids Supported by Recent Scientific Article 40
05/26/2016: PharmaCyte Biotech to Present Clinical Trial at Marcum MicroCap, ASCO and BIO International Conferences 41
04/25/2016: PharmaCyte Biotech’s Live-Cell Encapsulation Facility is Commissioned for GMP Manufacture 42
04/18/2017: PharmaCyte Biotech Discusses Future of Cannabis Research Program, Competitors and More with Program’s Director 43
04/10/2017: PharmaCyte Biotech’s Cannabis Research Program Sees Significant Progress in University of Northern Colorado Presentations 45
03/03/2016: PharmaCyte Biotech Reports on Audit of Live-Cell Encapsulation Facility by Chamow & Associates 47
03/01/2016: PharmaCyte Biotech Addresses Development of Targeted Cannabinoid Chemotherapy 48
02/26/2016: PharmaCyte Biotech Pancreatic Cancer Treatment to Target Recently Identified Forms of Pancreatic Cancer 49
Feb 13, 2017: PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity 50
Jan 25, 2016: PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial 52
01/24/2017: PharmaCyte Going Head to Head with Eli Lillys Pancreatic Cancer Drug in New Clinical Trial 53
01/19/2016: PharmaCyte Biotech Introduces Cell-in-a-Box as a Novel Treatment for Pancreatic Cancer and Potential Cure for Type 1 Diabetes 55
Jan 04, 2016: PharmaCyte Biotech Outlines 2016 Milestones as Its Pancreatic Cancer Treatment Moves Into a Clinical Trial 56
Product Approvals 57
Feb 13, 2017: PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity 57
Jan 30, 2017: PharmaCyte Biotech Retains Facet Life Sciences to Guide Pancreatic Cancer Therapy Development Lifecycle with FDA 59
Jan 04, 2017: PharmaCyte Biotech Announces Pre-IND Meeting Date with FDA 60
Dec 15, 2016: PharmaCyte Biotech Submits Pre-IND Meeting Package to FDA 61
Nov 29, 2016: PharmaCyte Biotech Granted FDA Pre-IND Meeting for Pancreatic Cancer Therapy 62
Nov 16, 2016: PharmaCyte Biotech Now Awaits U.S. FDA to Advance Pancreatic Cancer Therapy into Pivotal Clinical Trial 63
Nov 01, 2016: PharmaCyte Biotech Requests Pre-IND Meeting with FDA for its Pancreatic Cancer Clinical Trial 65
Apr 08, 2016: PharmaCyte Biotech’s Encapsulation Facility for Pancreatic Cancer Therapy Deemed Suitable by Thai FDA 66
Clinical Trials 67
Feb 21, 2017: PharmaCyte Biotech Discusses Patient Enrollment and TD2s Role in Upcoming Clinical Trial 67
Dec 12, 2016: PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial 69
Dec 07, 2016: PharmaCyte Biotech Discusses Upcoming Clinical Trial in Pancreatic Cancer with First Principal Investigator 71
Dec 01, 2016: PharmaCyte Biotech Moves Closer to Enrolling Patients in Pancreatic Cancer Clinical Trial 73
Oct 24, 2016: PharmaCyte Biotech Selects Dr. Manuel Hidalgo as Principal Investigator for Its Pancreatic Cancer Clinical Trial 75
Jun 23, 2016: PharmaCyte Biotech Releases Medical and Scientific Discussion from 2016 ASCO Annual Meeting 76
May 24, 2016: PharmaCyte Biotech to Engage Principal Investigator for Clinical Trial in Pancreatic Cancer 77
May 05, 2016: PharmaCyte Biotech Clears Major Milestone on Path to FDA Clinical Trial 78
Apr 06, 2016: PharmaCyte Biotech’s CEO Explains How New Clinical Trial Design Changed the GMP Certification Process 80
Mar 31, 2016: PharmaCyte Biotech Finalizes Design of Pancreatic Cancer Clinical Trial and Identifies Trial Sites under Consideration 81
Feb 24, 2016: PharmaCyte Biotech on Schedule for 2016 Cancer Clinical Trial in Pancreatic Cancer 82
Feb 22, 2016: PharmaCyte Biotech Issues Update on Preparations for Its Pancreatic Cancer Clinical Trial 83
Appendix 85
Methodology 85
About GlobalData 85
Contact Us 85
Disclaimer 85
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PharmaCyte Biotech Inc, Deals By Therapy Area, 2011 to YTD 2017 9
PharmaCyte Biotech Inc, Medical Devices Deals, 2011 to YTD 2017 10
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Nuvilex Acquires Rights To Live-Cell Encapsulation Technology For Diabetes From SG Austria 12
Nuvilex Acquires Pancreatic Cancer Treatment Technology 13
PharmaCyte Biotech Partners with Translational Drug Development and Clinical Network Services 14
PharmaCyte Biotech Enters into Co-Development Agreement with University of Technology Sydney 15
Nuvilex Enters into Licensing Agreement with University of Technology Sydney 16
PharmaCyte Biotech Raises USD1 Million in Private Placement of shares 17
Nuvilex to Raise up to USD50 Million in Public Offering of Shares 18
Nuvilex Completes First Tranche Of Private Placement Of Shares For US$2 Million 19
Nuvilex Competes Private Placement Of Securities For US$1.5 Million 20
Nuvilex Acquires 14.5% Stake In SGAustria, Life Science Company 21
Nuvilex Acquires Bio Blue Bird For US$1.5 Million 22
PharmaCyte Biotech Inc, Key Competitors 23
PharmaCyte Biotech Inc, Key Employees 24
PharmaCyte Biotech Inc, Subsidiaries 25